SlideShare ist ein Scribd-Unternehmen logo
1 von 32
Downloaden Sie, um offline zu lesen
1
Protocol Understanding
11/20/2017
Clinical Data Management (CDM)
Katalyst Healthcares & Life Sciences
Icons Used:
Questions
Demonstration
Hands on
Exercise
Coding
Standards
A Welcome
Break
Tools
Referenc
e
Test Your
Understandi
ng
Contacts
11/20/2017
2
• The protocol contains a study plan on which the clinical trial is based.
• Protocol is designed in such a way that it safeguards the health of the participants (while
limiting their financial liability) and also answer specific research questions
• Protocol lays out who, what, why, when, where, how about the clinical trial
• It safeguards clinical trial integrity
Protocol Understanding: Overview
3
Katalyst Healthcares & Life Sciences
After completing this chapter you will be able to:
– Understand protocol document
– Understand the contents of a protocol
– Understand the importance of protocol in clinical trials
Objectives:
4
Katalyst Healthcares & Life Sciences
• Protocol is a set of rules. Consider that you are driving a car. You have to follow some
set of rules while you are driving. Why are traffic rules required? These traffic rules
ensures that the transportation occurs in smooth and safe way. Similarly in Clinical
trials, the protocols were set up so that the transportation of clinical data across study
teams is smooth and safe
• CDISC is creating a standard called the Protocol Representation Model(PRM), which
identifies, defines and describes over 300 common protocol elements and maps those
elements to elements within the BRIDG model. The PRM model is intended as a
standard to be used in designing a study, selecting investigative sites, developing data
collection tools, and describing an analysis plan and study procedures
Do You Know:
5
Katalyst Healthcares & Life Sciences
• Amending the protocol immediately after an issue is discovered contributes
significantly to patient safety and overall success of the study
• The following practices should be followed during the design of electronic CRFs:
– The protocol should determine what data should be collected on the CRF
– All data must be collected on the CRF if specified in the protocol
Do You Know:
6
Katalyst Healthcares & Life Sciences
• A Clinical Trial Protocol is a document that describes the objective(s), design, methodology,
statistical considerations, and organization of a clinical trial.
- ICH-GCP Guidelines
Protocol Definition:
7
Katalyst Healthcares & Life Sciences
• The protocol gives the background and reason the trial is being conducted
• The protocol contains a study plan on which the clinical trial is based. The plan is designed to
safeguard the health of the participants (while limiting their financial liability) as well as answer
specific research questions
• The protocol describes, among other things, what types of people may participate in the trial;
the schedule of tests, procedures, medications, and dosages; and the length of the study
• While in a clinical trial, study participants are seen regularly by the research staff (usually
medical doctors and/or nurses) to monitor their health and to determine the safety and
effectiveness of the treatment(s) they are receiving
Protocol Overview:
8
Katalyst Healthcares & Life Sciences
Protocol - Cover Page:
9
Protocol Title: A randomized double blind placebo controlled study to investigate the safety of XYZ in healthy adult volunteers
Protocol Number: ABCD0001
Protocol Date: 10 October 2011
Study Phase: I
Project Leader: Jill J Jack
Protocol Author(s): A Fernandes PhD
B Neil PhD
C Frank PhD
Confidentiality Agreement
INVESTIGATOR: A Fernandes
TT Hospital
1st Floor, Ward 1A,
Delhi, India
SPONSOR: ABCL Ltd
The International Centre
Kensington SEZ,
PO Box X11, Mumbai, India
This document is a confidential communication of ABCL Ltd. Acceptance of this document constitutes the
agreement by the recipient that no unpublished information contained within will be published or disclosed
without prior written approval, except that this document may be disclosed to the appropriate Ethics
Committee and Regulatory Authority under the condition that they are requested to keep it confidential
Protocol Content
10
Katalyst Healthcares & Life Sciences
1. Background:
• Name and/or identity (i.e. chemical composition) of the investigational drug product(s) and the
disease or condition for which the investigational drug product(s) is (are) being evaluated
• Current status of the disease or condition for which the investigational drug(s) is (are) being
evaluated; to include current problems or deficiencies that warrant an evaluation of the
investigational drug
2. Rationale:
• Reason(s) why investigational drug(s) will be safe and effective for the clinical indication
• Description of, and justification for, the proposed route of administration, dosage, dosage regimen,
and duration of dosing of the investigational drug(s)
• Nature of the individuals (e.g., age range, sex, disease state or underlying condition) who will be
included in the proposed clinical evaluation of the investigational drug(s)
• If the investigational drug(s) has (have) been withdrawn from research or marketing in any country
for any reason related to its safety or effectiveness
1. Introduction:
11
Katalyst Healthcares & Life Sciences
2. Clinical Study Objectives:
12
This section includes:
1. Primary objective:
• Address the primary objective and specific aim(s) of the proposed clinical evaluation of the investigational
drug(s)
• Example: To lower the blood glucose level by 20 units
2. Secondary objectives:
• Address, if applicable, secondary objective(s) and specific aim(s) of the proposed clinical
evaluation of the investigational drug(s)
• Example: To improve the quality of life
3. Endpoints: These are outcome measures used to address the objectives of a clinical trial.
• The primary endpoint is the most important outcome and is used to assess the primary objective of a trial
• Example: The variable used to compare the effect difference of two treatment groups).
Katalyst Healthcares & Life Sciences
• The scientific integrity of the trial and the credibility of the data from the trial depend substantially on
the trial design. This includes:
1. A specific statement of the primary endpoints and the secondary endpoints, if any, to be
measured during the trial
2. A description of the type/design of trial to be conducted (e.g. double-blind, placebo-controlled,
parallel design) and a schematic diagram of trial design, procedures and stages
3. A description of the measures taken to minimize/avoid bias, including:(a) Randomization (b)
Blinding
4. A description of the trial treatment(s) and the dosage and dosage regimen of the investigational
product(s). Also include a description of the dosage form, packaging, and labeling of the
investigational product(s).
5. The expected duration of subject participation, and a description of the sequence and duration of
all trial periods, including follow-up, if any
3. Study Design:
13
Katalyst Healthcares & Life Sciences
6. A description of the “stopping rules” or
“discontinuation criteria” for individual subjects, parts
of trial and entire trial
7. Accountability procedures for the investigational
product(s), including the placebo(s) and
comparator(s), if any
8. Maintenance of trial treatment randomization codes
and procedures for breaking codes
9. The identification of any data to be recorded directly
on the CRFs (i.e. no prior written or electronic record of
data), and to be considered to be source data
3. Study Design contd..
14 Katalyst Healthcares & Life Sciences
3. Study Design contd:
15
1. Subject inclusion criteria
Inclusion criteria are characteristics that the prospective subjects must have if they are to be
included in the study
Example:
1. Study subjects must meet age (in years) and gender (men and women) criteria of the study
protocol.
2. Study subjects must meet disease criteria as specified by the study protocol.
2. Subject exclusion criteria
Exclusion criteria are those characteristics that disqualify prospective subjects from inclusion in
the study.
Example:
1. Study subjects must not have a medical history of sensitivity, intolerance, or toxicity to the
investigational product, or agents similar to the investigational product.
2. Study subjects must not have donated blood two months prior to study entry, and must not
donate blood after study entry until at least 30 days after the study subject has completed the
study.
4. Subject Selection:
16 Katalyst Healthcares & Life Sciences
3. Subject withdrawal criteria
(i.e. terminating investigational product treatment/trial treatment) and procedures specifying:
a. When and how to withdraw subjects from the trial/ investigational product treatment
b. The type and timing of the data to be collected for withdrawn subjects
c. Whether and how subjects are to be replaced
d. The follow-up for subjects withdrawn from investigational product treatment/trial
treatment
4. Subject Selection:
17
Katalyst Healthcares & Life Sciences
1. The treatment(s) to be administered, including the name(s) of all the product(s), the dose(s), the
dosing schedule(s), the route/mode(s) of administration, and the treatment period(s), including
the follow-up period(s) for subjects for each investigational product treatment/trial treatment
group/arm of the trial
2. Medication(s)/treatment(s) permitted (including rescue medication) and not permitted before
and/or during the trial
3. Procedures for monitoring subject compliance
4. Withdrawal of subjects due to non-compliance/ adherence
5. Study drug supplies:
 Formulation and packaging
 Preparing and dispensing
 Drug administration
6. Study drug storage and accountability
7. Description of Concomitant Medications and Rescue Medications.
5. Study Drug(s):
18 Katalyst Healthcares & Life Sciences
1. Screening procedures :
Description of the procedures performed at subject screening to verify subject eligibility for
study participation
2. Study drug procedures :
Description of the procedures performed for, and in association with, the administration of the
study drug(s)
3. Follow-up procedures (only if follow-up procedures will be performed)
 Description of follow-up procedures that will be performed after the subject completes the study drug
administration procedures
 Schedule of activities (Study Table)
 A table that summarizes the clinical protocol procedures; to include the procedures that will be
performed at screening, during the study drug administration, and at follow-up (if applicable) to the
study drug administration
6. Research Study Procedures:
19 Katalyst Healthcares & Life Sciences
Assessment of Safety :
1. Specification of safety parameters
2. The methods and timing for assessing, recording, and analyzing
safety parameters
3. Procedures for eliciting reports of and for recording and
reporting adverse event and inter-current illnesses
4. The type and duration of the follow-up of subjects after adverse
events
7. Safety and Efficacy Assessments:
20
Katalyst Healthcares & Life Sciences
Assessment of Efficacy :
1. Specification of the efficacy parameters
2. Methods and timing for assessing, recording, and analyzing of efficacy parameters
7. Safety and Efficacy Assessments contd..
21
1. Adverse event definitions
2. Recording/Reporting requirements :
 Eliciting adverse event information
 Recording requirements
3. Reporting of adverse reactions :
 Reporting of adverse reactions to the FDA
 Reporting adverse events to the responsible IRB
4. Withdrawal of subjects due to adverse events
8. Adverse Event Reporting:
22
1. A description of the statistical methods to be employed, including timing of any planned
interim analysis
2. The number of subjects planned to be enrolled. In multicenter trials, the numbers of enrolled
subjects projected for each trial site should be specified.
3. Reason for choice of sample size, including reflections on (or calculations of) the power of the
trial and clinical justification
4. The level of significance to be used
5. Criteria for the termination of the trial
6. Procedure for accounting for missing, unused, and spurious data
7. Procedures for reporting any deviation(s) from the original statistical plan (any deviation(s)
from the original statistical plan should be described and justified in protocol and/or in the final
report, as appropriate)
8. The selection of subjects to be included in the analyses (e.g. all randomized subjects, all dosed
subjects, all eligible subjects, evaluable subjects)
9. Statistical Methods/Data Analysis:
23
Description of nature and timing of the quality control/quality assurance reviews
(i.e., independent of the previously described monitoring activities) that will be undertaken by the
Sponsor-Investigator to ensure appropriate conduct of the clinical research study and quality and
completeness of the accrued study data. I.e., describe the data and safety monitoring plan for
the proposed clinical research study.
10. Quality Control and Quality Assurance:
24
Katalyst Healthcares & Life Sciences
1. Data recording/Case Report Forms : A Case Report Form (CRF) should be completed for each
subject enrolled into the clinical study. The Sponsor-Investigator will review, approve and
sign/date each completed CRF; the Sponsor-Investigator’s signature serving as attestation of
the Sponsor-Investigator’s responsibility for ensuring that all clinical and laboratory data
entered on the CRF are complete, accurate and authentic.
2. Record maintenance and retention : The Sponsor-Investigator will maintain records in
accordance with Good Clinical Practice guidelines.
11. Data Handling and Record-Keeping:
25
Katalyst Healthcares & Life Sciences
1. Institutional Review Board (IRB) approval
2. Ethical and scientific conduct of the clinical research study
3. Subject informed consent
12. Ethics:
26
Katalyst Healthcares & Life Sciences
• Discontinuation of individual research subjects : Addresses any discontinuation criteria or
“stopping rules” for individual research subjects that were not addressed previously under
section 5.1.1 (Withdrawal of subjects due to non-compliance/adherence) or section 8.4
(Withdrawal of subjects due to adverse events) of the clinical protocol.
• Sponsor-Investigator discontinuation of the clinical research study : Describes the
discontinuation criteria or “stopping rules” for parts of the clinical research study, if applicable,
or for the entire clinical research study.
13. Study Discontinuation Criteria:
27
Katalyst Healthcares & Life Sciences
• Lets see how does a protocol look like :
Lets discuss:
28
Katalyst Healthcares & Life Sciences
1. Define Protocol?
2. Which section of protocol describes procedures for monitoring subject compliance ?
3. Fill in the blank: The Sponsor-Investigator will maintain records in accordance with
________________
4. Procedures for reporting any deviation(s) from the original statistical plan described and
justified in __________and/or in the final report, as appropriate)
Test Your Understanding:
29
Katalyst Healthcares & Life Sciences
In this session the following topics were covered:
• Introduction to Clinical study protocol
• Contents of a protocol
• Importance of protocol in clinical trials
Summary:
30
Katalyst Healthcares & Life Sciences
You have successfully completed -
Protocol Understanding
Summary:
31
Katalyst Healthcares & Life Sciences
32
Thank You
&
Questions
Contact:
Katalyst Healthcare’s & Life Sciences
South Plainfield, NJ, USA 07080.
E-Mail: info@KatalystHLS.com

Weitere ähnliche Inhalte

Was ist angesagt?

Database Designing in Clinical Data Management
Database Designing in Clinical Data ManagementDatabase Designing in Clinical Data Management
Database Designing in Clinical Data ManagementClinosolIndia
 
Discrepany Management_Katalyst HLS
Discrepany Management_Katalyst HLSDiscrepany Management_Katalyst HLS
Discrepany Management_Katalyst HLSKatalyst HLS
 
Handling Third Party Vendor Data_Katalyst HLS
Handling Third Party Vendor Data_Katalyst HLSHandling Third Party Vendor Data_Katalyst HLS
Handling Third Party Vendor Data_Katalyst HLSKatalyst HLS
 
Data Management Plan_Katalyst HLS
Data Management Plan_Katalyst HLSData Management Plan_Katalyst HLS
Data Management Plan_Katalyst HLSKatalyst HLS
 
Clinical data management
Clinical data managementClinical data management
Clinical data managementAjay Murali
 
Safety_Data_Reconciliation_Katalyst HLS
Safety_Data_Reconciliation_Katalyst HLSSafety_Data_Reconciliation_Katalyst HLS
Safety_Data_Reconciliation_Katalyst HLSKatalyst HLS
 
Clinical Data Management Plan_Katalyst HLS
Clinical Data Management Plan_Katalyst HLSClinical Data Management Plan_Katalyst HLS
Clinical Data Management Plan_Katalyst HLSKatalyst HLS
 
Mock CRF Design_Katalyst HLS
Mock CRF Design_Katalyst HLSMock CRF Design_Katalyst HLS
Mock CRF Design_Katalyst HLSKatalyst HLS
 
Source Documents in Clinical Trials_part1
Source Documents in Clinical Trials_part1Source Documents in Clinical Trials_part1
Source Documents in Clinical Trials_part1Valentyna Korniyenko
 
Case Report Form (CRF) Design Tips
Case Report Form (CRF) Design TipsCase Report Form (CRF) Design Tips
Case Report Form (CRF) Design TipsPerficient
 
Clinical data-management-overview
Clinical data-management-overviewClinical data-management-overview
Clinical data-management-overviewAcri India
 
Medical Coding_Katalyst HLS
Medical Coding_Katalyst HLSMedical Coding_Katalyst HLS
Medical Coding_Katalyst HLSKatalyst HLS
 
Oracle Clinical Overview_Katalyst HLS
Oracle Clinical Overview_Katalyst HLSOracle Clinical Overview_Katalyst HLS
Oracle Clinical Overview_Katalyst HLSKatalyst HLS
 
TMF Fundamentals - An Introduction to Better Trial Master File Management - M...
TMF Fundamentals - An Introduction to Better Trial Master File Management - M...TMF Fundamentals - An Introduction to Better Trial Master File Management - M...
TMF Fundamentals - An Introduction to Better Trial Master File Management - M...Montrium
 
eTMF Structure, Setup, and Implementation Case Study
eTMF Structure, Setup, and Implementation Case StudyeTMF Structure, Setup, and Implementation Case Study
eTMF Structure, Setup, and Implementation Case StudyAdair Turner, MS, RAC
 
CLINICAL DATA MANAGEMENT.pptx
CLINICAL DATA MANAGEMENT.pptxCLINICAL DATA MANAGEMENT.pptx
CLINICAL DATA MANAGEMENT.pptxAkshata Kawaste
 
How to create edit checks in medidata rave painlessly
How to create edit checks in medidata rave painlesslyHow to create edit checks in medidata rave painlessly
How to create edit checks in medidata rave painlesslyWeihong Yang
 

Was ist angesagt? (20)

Database Designing in Clinical Data Management
Database Designing in Clinical Data ManagementDatabase Designing in Clinical Data Management
Database Designing in Clinical Data Management
 
Discrepany Management_Katalyst HLS
Discrepany Management_Katalyst HLSDiscrepany Management_Katalyst HLS
Discrepany Management_Katalyst HLS
 
Handling Third Party Vendor Data_Katalyst HLS
Handling Third Party Vendor Data_Katalyst HLSHandling Third Party Vendor Data_Katalyst HLS
Handling Third Party Vendor Data_Katalyst HLS
 
Data Management Plan_Katalyst HLS
Data Management Plan_Katalyst HLSData Management Plan_Katalyst HLS
Data Management Plan_Katalyst HLS
 
Clinical data management
Clinical data managementClinical data management
Clinical data management
 
CDM
CDMCDM
CDM
 
Safety_Data_Reconciliation_Katalyst HLS
Safety_Data_Reconciliation_Katalyst HLSSafety_Data_Reconciliation_Katalyst HLS
Safety_Data_Reconciliation_Katalyst HLS
 
Clinical Data Management Plan_Katalyst HLS
Clinical Data Management Plan_Katalyst HLSClinical Data Management Plan_Katalyst HLS
Clinical Data Management Plan_Katalyst HLS
 
CDISC-CDASH
CDISC-CDASHCDISC-CDASH
CDISC-CDASH
 
Mock CRF Design_Katalyst HLS
Mock CRF Design_Katalyst HLSMock CRF Design_Katalyst HLS
Mock CRF Design_Katalyst HLS
 
TMF PDF.pdf
TMF PDF.pdfTMF PDF.pdf
TMF PDF.pdf
 
Source Documents in Clinical Trials_part1
Source Documents in Clinical Trials_part1Source Documents in Clinical Trials_part1
Source Documents in Clinical Trials_part1
 
Case Report Form (CRF) Design Tips
Case Report Form (CRF) Design TipsCase Report Form (CRF) Design Tips
Case Report Form (CRF) Design Tips
 
Clinical data-management-overview
Clinical data-management-overviewClinical data-management-overview
Clinical data-management-overview
 
Medical Coding_Katalyst HLS
Medical Coding_Katalyst HLSMedical Coding_Katalyst HLS
Medical Coding_Katalyst HLS
 
Oracle Clinical Overview_Katalyst HLS
Oracle Clinical Overview_Katalyst HLSOracle Clinical Overview_Katalyst HLS
Oracle Clinical Overview_Katalyst HLS
 
TMF Fundamentals - An Introduction to Better Trial Master File Management - M...
TMF Fundamentals - An Introduction to Better Trial Master File Management - M...TMF Fundamentals - An Introduction to Better Trial Master File Management - M...
TMF Fundamentals - An Introduction to Better Trial Master File Management - M...
 
eTMF Structure, Setup, and Implementation Case Study
eTMF Structure, Setup, and Implementation Case StudyeTMF Structure, Setup, and Implementation Case Study
eTMF Structure, Setup, and Implementation Case Study
 
CLINICAL DATA MANAGEMENT.pptx
CLINICAL DATA MANAGEMENT.pptxCLINICAL DATA MANAGEMENT.pptx
CLINICAL DATA MANAGEMENT.pptx
 
How to create edit checks in medidata rave painlessly
How to create edit checks in medidata rave painlesslyHow to create edit checks in medidata rave painlessly
How to create edit checks in medidata rave painlessly
 

Ähnlich wie Protocol Understanding_Katalyst HLS

Protocol development
Protocol developmentProtocol development
Protocol developmentAlisha Bansal
 
planning and initiation.pptx
planning and initiation.pptxplanning and initiation.pptx
planning and initiation.pptxseeja2
 
4. Unit-IV:- Clinical Trials.
4. Unit-IV:- Clinical Trials.4. Unit-IV:- Clinical Trials.
4. Unit-IV:- Clinical Trials.Audumbar Mali
 
Development of clinical trail protocol
Development of clinical trail protocolDevelopment of clinical trail protocol
Development of clinical trail protocolPradnya Shirude
 
DEVELOPING CLINICAL TRIAL PROTOCOL BY PRANAV LENDHEY.pptx
DEVELOPING CLINICAL TRIAL PROTOCOL BY PRANAV LENDHEY.pptxDEVELOPING CLINICAL TRIAL PROTOCOL BY PRANAV LENDHEY.pptx
DEVELOPING CLINICAL TRIAL PROTOCOL BY PRANAV LENDHEY.pptx36PranavLendhey
 
CLINICAL TRAIL (TRIAL PROTOCOL & INSTITUTIONAL REVIEW BOARD/ INDEPENDENT ETHI...
CLINICAL TRAIL (TRIAL PROTOCOL & INSTITUTIONAL REVIEW BOARD/ INDEPENDENT ETHI...CLINICAL TRAIL (TRIAL PROTOCOL & INSTITUTIONAL REVIEW BOARD/ INDEPENDENT ETHI...
CLINICAL TRAIL (TRIAL PROTOCOL & INSTITUTIONAL REVIEW BOARD/ INDEPENDENT ETHI...amitsoni240
 
Roles and responsibilities in clinical trials
Roles and responsibilities in clinical trialsRoles and responsibilities in clinical trials
Roles and responsibilities in clinical trialsDRx Tejas Kanhed
 
Preparation of Clinical Trial Protocol of India.
Preparation of Clinical Trial Protocol of India.Preparation of Clinical Trial Protocol of India.
Preparation of Clinical Trial Protocol of India.Aakashdeep Raval
 
GCP for Investigators by Valentyna
GCP for Investigators by ValentynaGCP for Investigators by Valentyna
GCP for Investigators by ValentynaValentyna Korniyenko
 
What is The Clinical Trial Approval Process In India.pdf
What is The Clinical Trial Approval Process In India.pdfWhat is The Clinical Trial Approval Process In India.pdf
What is The Clinical Trial Approval Process In India.pdfPranshuCorpseed
 
Interview Question Series: Clinical Research
Interview Question Series: Clinical ResearchInterview Question Series: Clinical Research
Interview Question Series: Clinical ResearchClinosolIndia
 
Clinical Trial Protocol
Clinical Trial ProtocolClinical Trial Protocol
Clinical Trial ProtocolClinosolIndia
 
FDA 2013 Clinical Investigator Training Course: Preparing an IND Application:...
FDA 2013 Clinical Investigator Training Course: Preparing an IND Application:...FDA 2013 Clinical Investigator Training Course: Preparing an IND Application:...
FDA 2013 Clinical Investigator Training Course: Preparing an IND Application:...MedicReS
 

Ähnlich wie Protocol Understanding_Katalyst HLS (20)

DEVELOPING THE CLINICAL TRIAL PROTOCOL | PPT
DEVELOPING THE CLINICAL TRIAL PROTOCOL | PPTDEVELOPING THE CLINICAL TRIAL PROTOCOL | PPT
DEVELOPING THE CLINICAL TRIAL PROTOCOL | PPT
 
Preparation of protocol
Preparation of protocolPreparation of protocol
Preparation of protocol
 
Protocol development
Protocol developmentProtocol development
Protocol development
 
Clinical research protocol
Clinical research protocolClinical research protocol
Clinical research protocol
 
planning and initiation.pptx
planning and initiation.pptxplanning and initiation.pptx
planning and initiation.pptx
 
Turacoz - Clinical Study Report
Turacoz - Clinical Study ReportTuracoz - Clinical Study Report
Turacoz - Clinical Study Report
 
4. Unit-IV:- Clinical Trials.
4. Unit-IV:- Clinical Trials.4. Unit-IV:- Clinical Trials.
4. Unit-IV:- Clinical Trials.
 
Development of clinical trail protocol
Development of clinical trail protocolDevelopment of clinical trail protocol
Development of clinical trail protocol
 
DEVELOPING CLINICAL TRIAL PROTOCOL BY PRANAV LENDHEY.pptx
DEVELOPING CLINICAL TRIAL PROTOCOL BY PRANAV LENDHEY.pptxDEVELOPING CLINICAL TRIAL PROTOCOL BY PRANAV LENDHEY.pptx
DEVELOPING CLINICAL TRIAL PROTOCOL BY PRANAV LENDHEY.pptx
 
Protocol
ProtocolProtocol
Protocol
 
CLINICAL TRAIL (TRIAL PROTOCOL & INSTITUTIONAL REVIEW BOARD/ INDEPENDENT ETHI...
CLINICAL TRAIL (TRIAL PROTOCOL & INSTITUTIONAL REVIEW BOARD/ INDEPENDENT ETHI...CLINICAL TRAIL (TRIAL PROTOCOL & INSTITUTIONAL REVIEW BOARD/ INDEPENDENT ETHI...
CLINICAL TRAIL (TRIAL PROTOCOL & INSTITUTIONAL REVIEW BOARD/ INDEPENDENT ETHI...
 
Roles and responsibilities in clinical trials
Roles and responsibilities in clinical trialsRoles and responsibilities in clinical trials
Roles and responsibilities in clinical trials
 
Preparation of Clinical Trial Protocol of India.
Preparation of Clinical Trial Protocol of India.Preparation of Clinical Trial Protocol of India.
Preparation of Clinical Trial Protocol of India.
 
58541541-GCP-GMP
58541541-GCP-GMP58541541-GCP-GMP
58541541-GCP-GMP
 
GCP for Investigators by Valentyna
GCP for Investigators by ValentynaGCP for Investigators by Valentyna
GCP for Investigators by Valentyna
 
What is The Clinical Trial Approval Process In India.pdf
What is The Clinical Trial Approval Process In India.pdfWhat is The Clinical Trial Approval Process In India.pdf
What is The Clinical Trial Approval Process In India.pdf
 
Professor Peivand Pirouzi - International clinical study and safety reporting...
Professor Peivand Pirouzi - International clinical study and safety reporting...Professor Peivand Pirouzi - International clinical study and safety reporting...
Professor Peivand Pirouzi - International clinical study and safety reporting...
 
Interview Question Series: Clinical Research
Interview Question Series: Clinical ResearchInterview Question Series: Clinical Research
Interview Question Series: Clinical Research
 
Clinical Trial Protocol
Clinical Trial ProtocolClinical Trial Protocol
Clinical Trial Protocol
 
FDA 2013 Clinical Investigator Training Course: Preparing an IND Application:...
FDA 2013 Clinical Investigator Training Course: Preparing an IND Application:...FDA 2013 Clinical Investigator Training Course: Preparing an IND Application:...
FDA 2013 Clinical Investigator Training Course: Preparing an IND Application:...
 

Mehr von Katalyst HLS

Risk Based Approach CSV Training_Katalyst HLS
Risk Based Approach CSV Training_Katalyst HLSRisk Based Approach CSV Training_Katalyst HLS
Risk Based Approach CSV Training_Katalyst HLSKatalyst HLS
 
21 CFR Part11_CSV Training_Katalyst HLS
21 CFR Part11_CSV Training_Katalyst HLS21 CFR Part11_CSV Training_Katalyst HLS
21 CFR Part11_CSV Training_Katalyst HLSKatalyst HLS
 
Oracle Study Setup_Katalyst HLS
Oracle Study Setup_Katalyst HLSOracle Study Setup_Katalyst HLS
Oracle Study Setup_Katalyst HLSKatalyst HLS
 
Oracle Clinical Overview_Katalyst HLS
Oracle Clinical Overview_Katalyst HLSOracle Clinical Overview_Katalyst HLS
Oracle Clinical Overview_Katalyst HLSKatalyst HLS
 
OCRDC Graphical Layout Features_Katalyst HLS
OCRDC Graphical Layout Features_Katalyst HLSOCRDC Graphical Layout Features_Katalyst HLS
OCRDC Graphical Layout Features_Katalyst HLSKatalyst HLS
 
OC Procedure Progarmming Module_Katalyst HLS
OC Procedure Progarmming Module_Katalyst HLSOC Procedure Progarmming Module_Katalyst HLS
OC Procedure Progarmming Module_Katalyst HLSKatalyst HLS
 
OC Backend_Katalyst HLS
OC Backend_Katalyst HLSOC Backend_Katalyst HLS
OC Backend_Katalyst HLSKatalyst HLS
 
Labs Module_Katalyst HLS
Labs Module_Katalyst HLSLabs Module_Katalyst HLS
Labs Module_Katalyst HLSKatalyst HLS
 
Discovery of Drug and Introduction to Clinical Trial__Katalyst HLS
Discovery of Drug and Introduction to Clinical Trial__Katalyst HLSDiscovery of Drug and Introduction to Clinical Trial__Katalyst HLS
Discovery of Drug and Introduction to Clinical Trial__Katalyst HLSKatalyst HLS
 
Data Loading and Data Entry_Katalyst HLS
Data Loading and Data Entry_Katalyst HLSData Loading and Data Entry_Katalyst HLS
Data Loading and Data Entry_Katalyst HLSKatalyst HLS
 
Data Extract Views_Katalyst HLS
Data Extract Views_Katalyst HLSData Extract Views_Katalyst HLS
Data Extract Views_Katalyst HLSKatalyst HLS
 
Data Capture And Validation_Katalyst HLS
Data Capture And Validation_Katalyst HLSData Capture And Validation_Katalyst HLS
Data Capture And Validation_Katalyst HLSKatalyst HLS
 
Clean File_Form_Lock_Katalyst HLS
Clean File_Form_Lock_Katalyst HLSClean File_Form_Lock_Katalyst HLS
Clean File_Form_Lock_Katalyst HLSKatalyst HLS
 
Audits & Inspections_Katalyst HLS
Audits & Inspections_Katalyst HLSAudits & Inspections_Katalyst HLS
Audits & Inspections_Katalyst HLSKatalyst HLS
 
Aggregate Reporting_Pharmacovigilance_Katalyst HLS
Aggregate Reporting_Pharmacovigilance_Katalyst HLSAggregate Reporting_Pharmacovigilance_Katalyst HLS
Aggregate Reporting_Pharmacovigilance_Katalyst HLSKatalyst HLS
 
Overview of Validation in Pharma_Katalyst HLS
Overview of Validation in Pharma_Katalyst HLSOverview of Validation in Pharma_Katalyst HLS
Overview of Validation in Pharma_Katalyst HLSKatalyst HLS
 
Argus Aggregrate Reporting_Katalyst HLS
Argus Aggregrate Reporting_Katalyst HLSArgus Aggregrate Reporting_Katalyst HLS
Argus Aggregrate Reporting_Katalyst HLSKatalyst HLS
 
All about Clinical Trials_Katalyst HLS
All about Clinical Trials_Katalyst HLSAll about Clinical Trials_Katalyst HLS
All about Clinical Trials_Katalyst HLSKatalyst HLS
 
Reconciliation and Literature Review and Signal Detection_Katalyst HLS
Reconciliation and Literature Review and Signal Detection_Katalyst HLSReconciliation and Literature Review and Signal Detection_Katalyst HLS
Reconciliation and Literature Review and Signal Detection_Katalyst HLSKatalyst HLS
 

Mehr von Katalyst HLS (19)

Risk Based Approach CSV Training_Katalyst HLS
Risk Based Approach CSV Training_Katalyst HLSRisk Based Approach CSV Training_Katalyst HLS
Risk Based Approach CSV Training_Katalyst HLS
 
21 CFR Part11_CSV Training_Katalyst HLS
21 CFR Part11_CSV Training_Katalyst HLS21 CFR Part11_CSV Training_Katalyst HLS
21 CFR Part11_CSV Training_Katalyst HLS
 
Oracle Study Setup_Katalyst HLS
Oracle Study Setup_Katalyst HLSOracle Study Setup_Katalyst HLS
Oracle Study Setup_Katalyst HLS
 
Oracle Clinical Overview_Katalyst HLS
Oracle Clinical Overview_Katalyst HLSOracle Clinical Overview_Katalyst HLS
Oracle Clinical Overview_Katalyst HLS
 
OCRDC Graphical Layout Features_Katalyst HLS
OCRDC Graphical Layout Features_Katalyst HLSOCRDC Graphical Layout Features_Katalyst HLS
OCRDC Graphical Layout Features_Katalyst HLS
 
OC Procedure Progarmming Module_Katalyst HLS
OC Procedure Progarmming Module_Katalyst HLSOC Procedure Progarmming Module_Katalyst HLS
OC Procedure Progarmming Module_Katalyst HLS
 
OC Backend_Katalyst HLS
OC Backend_Katalyst HLSOC Backend_Katalyst HLS
OC Backend_Katalyst HLS
 
Labs Module_Katalyst HLS
Labs Module_Katalyst HLSLabs Module_Katalyst HLS
Labs Module_Katalyst HLS
 
Discovery of Drug and Introduction to Clinical Trial__Katalyst HLS
Discovery of Drug and Introduction to Clinical Trial__Katalyst HLSDiscovery of Drug and Introduction to Clinical Trial__Katalyst HLS
Discovery of Drug and Introduction to Clinical Trial__Katalyst HLS
 
Data Loading and Data Entry_Katalyst HLS
Data Loading and Data Entry_Katalyst HLSData Loading and Data Entry_Katalyst HLS
Data Loading and Data Entry_Katalyst HLS
 
Data Extract Views_Katalyst HLS
Data Extract Views_Katalyst HLSData Extract Views_Katalyst HLS
Data Extract Views_Katalyst HLS
 
Data Capture And Validation_Katalyst HLS
Data Capture And Validation_Katalyst HLSData Capture And Validation_Katalyst HLS
Data Capture And Validation_Katalyst HLS
 
Clean File_Form_Lock_Katalyst HLS
Clean File_Form_Lock_Katalyst HLSClean File_Form_Lock_Katalyst HLS
Clean File_Form_Lock_Katalyst HLS
 
Audits & Inspections_Katalyst HLS
Audits & Inspections_Katalyst HLSAudits & Inspections_Katalyst HLS
Audits & Inspections_Katalyst HLS
 
Aggregate Reporting_Pharmacovigilance_Katalyst HLS
Aggregate Reporting_Pharmacovigilance_Katalyst HLSAggregate Reporting_Pharmacovigilance_Katalyst HLS
Aggregate Reporting_Pharmacovigilance_Katalyst HLS
 
Overview of Validation in Pharma_Katalyst HLS
Overview of Validation in Pharma_Katalyst HLSOverview of Validation in Pharma_Katalyst HLS
Overview of Validation in Pharma_Katalyst HLS
 
Argus Aggregrate Reporting_Katalyst HLS
Argus Aggregrate Reporting_Katalyst HLSArgus Aggregrate Reporting_Katalyst HLS
Argus Aggregrate Reporting_Katalyst HLS
 
All about Clinical Trials_Katalyst HLS
All about Clinical Trials_Katalyst HLSAll about Clinical Trials_Katalyst HLS
All about Clinical Trials_Katalyst HLS
 
Reconciliation and Literature Review and Signal Detection_Katalyst HLS
Reconciliation and Literature Review and Signal Detection_Katalyst HLSReconciliation and Literature Review and Signal Detection_Katalyst HLS
Reconciliation and Literature Review and Signal Detection_Katalyst HLS
 

Kürzlich hochgeladen

Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024EwoutSteyerberg1
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologyDeepakDaniel9
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxMAsifAhmad
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectiondrhanifmohdali
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfDolisha Warbi
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Peter Embi
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdfHongBiThi1
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaSujoy Dasgupta
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxkomalt2001
 
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdfHongBiThi1
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfDolisha Warbi
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismusChandrasekar Reddy
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...Sujoy Dasgupta
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyZurück zum Ursprung
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationMedicoseAcademics
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu Medical University
 

Kürzlich hochgeladen (20)

Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacology
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissection
 
Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024
 
American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
 
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
 
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptx
 
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismus
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturally
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu
 

Protocol Understanding_Katalyst HLS

  • 1. 1 Protocol Understanding 11/20/2017 Clinical Data Management (CDM) Katalyst Healthcares & Life Sciences
  • 2. Icons Used: Questions Demonstration Hands on Exercise Coding Standards A Welcome Break Tools Referenc e Test Your Understandi ng Contacts 11/20/2017 2
  • 3. • The protocol contains a study plan on which the clinical trial is based. • Protocol is designed in such a way that it safeguards the health of the participants (while limiting their financial liability) and also answer specific research questions • Protocol lays out who, what, why, when, where, how about the clinical trial • It safeguards clinical trial integrity Protocol Understanding: Overview 3 Katalyst Healthcares & Life Sciences
  • 4. After completing this chapter you will be able to: – Understand protocol document – Understand the contents of a protocol – Understand the importance of protocol in clinical trials Objectives: 4 Katalyst Healthcares & Life Sciences
  • 5. • Protocol is a set of rules. Consider that you are driving a car. You have to follow some set of rules while you are driving. Why are traffic rules required? These traffic rules ensures that the transportation occurs in smooth and safe way. Similarly in Clinical trials, the protocols were set up so that the transportation of clinical data across study teams is smooth and safe • CDISC is creating a standard called the Protocol Representation Model(PRM), which identifies, defines and describes over 300 common protocol elements and maps those elements to elements within the BRIDG model. The PRM model is intended as a standard to be used in designing a study, selecting investigative sites, developing data collection tools, and describing an analysis plan and study procedures Do You Know: 5 Katalyst Healthcares & Life Sciences
  • 6. • Amending the protocol immediately after an issue is discovered contributes significantly to patient safety and overall success of the study • The following practices should be followed during the design of electronic CRFs: – The protocol should determine what data should be collected on the CRF – All data must be collected on the CRF if specified in the protocol Do You Know: 6 Katalyst Healthcares & Life Sciences
  • 7. • A Clinical Trial Protocol is a document that describes the objective(s), design, methodology, statistical considerations, and organization of a clinical trial. - ICH-GCP Guidelines Protocol Definition: 7 Katalyst Healthcares & Life Sciences
  • 8. • The protocol gives the background and reason the trial is being conducted • The protocol contains a study plan on which the clinical trial is based. The plan is designed to safeguard the health of the participants (while limiting their financial liability) as well as answer specific research questions • The protocol describes, among other things, what types of people may participate in the trial; the schedule of tests, procedures, medications, and dosages; and the length of the study • While in a clinical trial, study participants are seen regularly by the research staff (usually medical doctors and/or nurses) to monitor their health and to determine the safety and effectiveness of the treatment(s) they are receiving Protocol Overview: 8 Katalyst Healthcares & Life Sciences
  • 9. Protocol - Cover Page: 9 Protocol Title: A randomized double blind placebo controlled study to investigate the safety of XYZ in healthy adult volunteers Protocol Number: ABCD0001 Protocol Date: 10 October 2011 Study Phase: I Project Leader: Jill J Jack Protocol Author(s): A Fernandes PhD B Neil PhD C Frank PhD Confidentiality Agreement INVESTIGATOR: A Fernandes TT Hospital 1st Floor, Ward 1A, Delhi, India SPONSOR: ABCL Ltd The International Centre Kensington SEZ, PO Box X11, Mumbai, India This document is a confidential communication of ABCL Ltd. Acceptance of this document constitutes the agreement by the recipient that no unpublished information contained within will be published or disclosed without prior written approval, except that this document may be disclosed to the appropriate Ethics Committee and Regulatory Authority under the condition that they are requested to keep it confidential
  • 11. 1. Background: • Name and/or identity (i.e. chemical composition) of the investigational drug product(s) and the disease or condition for which the investigational drug product(s) is (are) being evaluated • Current status of the disease or condition for which the investigational drug(s) is (are) being evaluated; to include current problems or deficiencies that warrant an evaluation of the investigational drug 2. Rationale: • Reason(s) why investigational drug(s) will be safe and effective for the clinical indication • Description of, and justification for, the proposed route of administration, dosage, dosage regimen, and duration of dosing of the investigational drug(s) • Nature of the individuals (e.g., age range, sex, disease state or underlying condition) who will be included in the proposed clinical evaluation of the investigational drug(s) • If the investigational drug(s) has (have) been withdrawn from research or marketing in any country for any reason related to its safety or effectiveness 1. Introduction: 11 Katalyst Healthcares & Life Sciences
  • 12. 2. Clinical Study Objectives: 12 This section includes: 1. Primary objective: • Address the primary objective and specific aim(s) of the proposed clinical evaluation of the investigational drug(s) • Example: To lower the blood glucose level by 20 units 2. Secondary objectives: • Address, if applicable, secondary objective(s) and specific aim(s) of the proposed clinical evaluation of the investigational drug(s) • Example: To improve the quality of life 3. Endpoints: These are outcome measures used to address the objectives of a clinical trial. • The primary endpoint is the most important outcome and is used to assess the primary objective of a trial • Example: The variable used to compare the effect difference of two treatment groups). Katalyst Healthcares & Life Sciences
  • 13. • The scientific integrity of the trial and the credibility of the data from the trial depend substantially on the trial design. This includes: 1. A specific statement of the primary endpoints and the secondary endpoints, if any, to be measured during the trial 2. A description of the type/design of trial to be conducted (e.g. double-blind, placebo-controlled, parallel design) and a schematic diagram of trial design, procedures and stages 3. A description of the measures taken to minimize/avoid bias, including:(a) Randomization (b) Blinding 4. A description of the trial treatment(s) and the dosage and dosage regimen of the investigational product(s). Also include a description of the dosage form, packaging, and labeling of the investigational product(s). 5. The expected duration of subject participation, and a description of the sequence and duration of all trial periods, including follow-up, if any 3. Study Design: 13 Katalyst Healthcares & Life Sciences
  • 14. 6. A description of the “stopping rules” or “discontinuation criteria” for individual subjects, parts of trial and entire trial 7. Accountability procedures for the investigational product(s), including the placebo(s) and comparator(s), if any 8. Maintenance of trial treatment randomization codes and procedures for breaking codes 9. The identification of any data to be recorded directly on the CRFs (i.e. no prior written or electronic record of data), and to be considered to be source data 3. Study Design contd.. 14 Katalyst Healthcares & Life Sciences
  • 15. 3. Study Design contd: 15
  • 16. 1. Subject inclusion criteria Inclusion criteria are characteristics that the prospective subjects must have if they are to be included in the study Example: 1. Study subjects must meet age (in years) and gender (men and women) criteria of the study protocol. 2. Study subjects must meet disease criteria as specified by the study protocol. 2. Subject exclusion criteria Exclusion criteria are those characteristics that disqualify prospective subjects from inclusion in the study. Example: 1. Study subjects must not have a medical history of sensitivity, intolerance, or toxicity to the investigational product, or agents similar to the investigational product. 2. Study subjects must not have donated blood two months prior to study entry, and must not donate blood after study entry until at least 30 days after the study subject has completed the study. 4. Subject Selection: 16 Katalyst Healthcares & Life Sciences
  • 17. 3. Subject withdrawal criteria (i.e. terminating investigational product treatment/trial treatment) and procedures specifying: a. When and how to withdraw subjects from the trial/ investigational product treatment b. The type and timing of the data to be collected for withdrawn subjects c. Whether and how subjects are to be replaced d. The follow-up for subjects withdrawn from investigational product treatment/trial treatment 4. Subject Selection: 17 Katalyst Healthcares & Life Sciences
  • 18. 1. The treatment(s) to be administered, including the name(s) of all the product(s), the dose(s), the dosing schedule(s), the route/mode(s) of administration, and the treatment period(s), including the follow-up period(s) for subjects for each investigational product treatment/trial treatment group/arm of the trial 2. Medication(s)/treatment(s) permitted (including rescue medication) and not permitted before and/or during the trial 3. Procedures for monitoring subject compliance 4. Withdrawal of subjects due to non-compliance/ adherence 5. Study drug supplies:  Formulation and packaging  Preparing and dispensing  Drug administration 6. Study drug storage and accountability 7. Description of Concomitant Medications and Rescue Medications. 5. Study Drug(s): 18 Katalyst Healthcares & Life Sciences
  • 19. 1. Screening procedures : Description of the procedures performed at subject screening to verify subject eligibility for study participation 2. Study drug procedures : Description of the procedures performed for, and in association with, the administration of the study drug(s) 3. Follow-up procedures (only if follow-up procedures will be performed)  Description of follow-up procedures that will be performed after the subject completes the study drug administration procedures  Schedule of activities (Study Table)  A table that summarizes the clinical protocol procedures; to include the procedures that will be performed at screening, during the study drug administration, and at follow-up (if applicable) to the study drug administration 6. Research Study Procedures: 19 Katalyst Healthcares & Life Sciences
  • 20. Assessment of Safety : 1. Specification of safety parameters 2. The methods and timing for assessing, recording, and analyzing safety parameters 3. Procedures for eliciting reports of and for recording and reporting adverse event and inter-current illnesses 4. The type and duration of the follow-up of subjects after adverse events 7. Safety and Efficacy Assessments: 20 Katalyst Healthcares & Life Sciences
  • 21. Assessment of Efficacy : 1. Specification of the efficacy parameters 2. Methods and timing for assessing, recording, and analyzing of efficacy parameters 7. Safety and Efficacy Assessments contd.. 21
  • 22. 1. Adverse event definitions 2. Recording/Reporting requirements :  Eliciting adverse event information  Recording requirements 3. Reporting of adverse reactions :  Reporting of adverse reactions to the FDA  Reporting adverse events to the responsible IRB 4. Withdrawal of subjects due to adverse events 8. Adverse Event Reporting: 22
  • 23. 1. A description of the statistical methods to be employed, including timing of any planned interim analysis 2. The number of subjects planned to be enrolled. In multicenter trials, the numbers of enrolled subjects projected for each trial site should be specified. 3. Reason for choice of sample size, including reflections on (or calculations of) the power of the trial and clinical justification 4. The level of significance to be used 5. Criteria for the termination of the trial 6. Procedure for accounting for missing, unused, and spurious data 7. Procedures for reporting any deviation(s) from the original statistical plan (any deviation(s) from the original statistical plan should be described and justified in protocol and/or in the final report, as appropriate) 8. The selection of subjects to be included in the analyses (e.g. all randomized subjects, all dosed subjects, all eligible subjects, evaluable subjects) 9. Statistical Methods/Data Analysis: 23
  • 24. Description of nature and timing of the quality control/quality assurance reviews (i.e., independent of the previously described monitoring activities) that will be undertaken by the Sponsor-Investigator to ensure appropriate conduct of the clinical research study and quality and completeness of the accrued study data. I.e., describe the data and safety monitoring plan for the proposed clinical research study. 10. Quality Control and Quality Assurance: 24 Katalyst Healthcares & Life Sciences
  • 25. 1. Data recording/Case Report Forms : A Case Report Form (CRF) should be completed for each subject enrolled into the clinical study. The Sponsor-Investigator will review, approve and sign/date each completed CRF; the Sponsor-Investigator’s signature serving as attestation of the Sponsor-Investigator’s responsibility for ensuring that all clinical and laboratory data entered on the CRF are complete, accurate and authentic. 2. Record maintenance and retention : The Sponsor-Investigator will maintain records in accordance with Good Clinical Practice guidelines. 11. Data Handling and Record-Keeping: 25 Katalyst Healthcares & Life Sciences
  • 26. 1. Institutional Review Board (IRB) approval 2. Ethical and scientific conduct of the clinical research study 3. Subject informed consent 12. Ethics: 26 Katalyst Healthcares & Life Sciences
  • 27. • Discontinuation of individual research subjects : Addresses any discontinuation criteria or “stopping rules” for individual research subjects that were not addressed previously under section 5.1.1 (Withdrawal of subjects due to non-compliance/adherence) or section 8.4 (Withdrawal of subjects due to adverse events) of the clinical protocol. • Sponsor-Investigator discontinuation of the clinical research study : Describes the discontinuation criteria or “stopping rules” for parts of the clinical research study, if applicable, or for the entire clinical research study. 13. Study Discontinuation Criteria: 27 Katalyst Healthcares & Life Sciences
  • 28. • Lets see how does a protocol look like : Lets discuss: 28 Katalyst Healthcares & Life Sciences
  • 29. 1. Define Protocol? 2. Which section of protocol describes procedures for monitoring subject compliance ? 3. Fill in the blank: The Sponsor-Investigator will maintain records in accordance with ________________ 4. Procedures for reporting any deviation(s) from the original statistical plan described and justified in __________and/or in the final report, as appropriate) Test Your Understanding: 29 Katalyst Healthcares & Life Sciences
  • 30. In this session the following topics were covered: • Introduction to Clinical study protocol • Contents of a protocol • Importance of protocol in clinical trials Summary: 30 Katalyst Healthcares & Life Sciences
  • 31. You have successfully completed - Protocol Understanding Summary: 31 Katalyst Healthcares & Life Sciences
  • 32. 32 Thank You & Questions Contact: Katalyst Healthcare’s & Life Sciences South Plainfield, NJ, USA 07080. E-Mail: info@KatalystHLS.com